BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalin B, van Norden Y, van Gelder M, Breems D, Maertens J, Jongen-Lavrencic M, Broers AEC, Braakman E, Grob T, Zeijlemaker W, Ossenkoppele GJ, Meijer E, Cornelissen JJ. Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. Blood Adv 2020;4:4430-7. [PMID: 32936907 DOI: 10.1182/bloodadvances.2020002074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Schmid C, Kuball J, Bug G. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. J Clin Oncol 2021;39:397-418. [PMID: 33434060 DOI: 10.1200/JCO.20.01719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ye Y, Yang L, Yuan X, Huang H, Luo Y. Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering. Front Oncol 2021;11:790299. [PMID: 35155192 DOI: 10.3389/fonc.2021.790299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Leotta S, Condorelli A, Sciortino R, Milone GA, Bellofiore C, Garibaldi B, Schininà G, Spadaro A, Cupri A, Milone G. Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives. J Clin Med 2022;11:253. [PMID: 35011994 DOI: 10.3390/jcm11010253] [Reference Citation Analysis]
4 Ciotti G, Marconi G, Martinelli G. Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. Front Oncol 2021;11:810387. [PMID: 35071015 DOI: 10.3389/fonc.2021.810387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bruserud Ø, Tsykunova G, Hernandez-Valladares M, Reikvam H, Tvedt THA. Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. Pharmaceuticals (Basel) 2021;14:423. [PMID: 34063204 DOI: 10.3390/ph14050423] [Reference Citation Analysis]
6 Benincasa G, Vasco M, Corrado A, Sansone A, Picascia A, Napoli C. Epigenetic-based therapy in allogenic hematopoietic stem cell transplantation: Novel opportunities for personalized treatment. Clin Transplant 2021;:e14306. [PMID: 33792965 DOI: 10.1111/ctr.14306] [Reference Citation Analysis]
7 Guillaume T, Thépot S, Peterlin P, Ceballos P, Bourgeois AL, Garnier A, Orvain C, Giltat A, François S, Bris YL, Fronteau C, Planche L, Chevallier P. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Transplant Cell Ther 2021:S2666-6367(21)01032-0. [PMID: 34224913 DOI: 10.1016/j.jtct.2021.06.029] [Reference Citation Analysis]